title: Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study.
abstract: The purpose of this study was to investigate the safety profile of SR29142 when administered as a single agent both prior to chemotherapy and during treatment, and to compare the efficacy of SR29142 administered at two dose levels in adult Japanese patients with leukemia or lymphoma. During this open-label, multicenter, phase II study, patients received SR29142 for 5 days, administered at either 0.15 or 0.20 mg/kg per day. Chemotherapy was started 4–24 h after the first infusion of SR29142. The primary end-point was overall response rate, defined as the normalization of plasma uric acid to 7.5 mg/dL or less, from 48 h after the first infusion to 24 h after the last infusion of SR29142. SR29142-related adverse events including hypersensitivity (allergic) reactions were assessed. Overall, 50 patients received SR29142 at either 0.15 mg/kg per day (n = 25) or 0.20 mg/kg per day (n = 25) followed by chemotherapy. The overall response rate was 100.0% (95% confidence interval, 86.3–100.0%) with 0.15 mg/kg and 96.0% (95% confidence interval, 79.6–99.9%) with 0.20 mg/kg. Both dose levels of SR29142 were equally effective at reducing plasma uric acid levels. In six patients, seven drug-related adverse events of grade 1/2 occurred before chemotherapy. SR29142-related, hypersensitivity-associated reactions occurred in three patients, and rash, anorexia, application site pain and pyrexia occurred in one patient each; only five patients (10%) showed anti-SR29142 antibodies by day 29. In conclusion, SR29142 is effective at reducing plasma uric acid levels with a tolerable safety profile as a single agent both prior to chemotherapy and during treatment.
authors.affiliation: Department of Rheumatology and Hematology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan. kishizaw@mail.tains.tohoku.ac.jp
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ishizawa
authors.forename: Michinori
authors.initials: M
authors.lastname: Ogura
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hamaguchi
authors.forename: Tomomitsu
authors.initials: T
authors.lastname: Hotta
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ohnishi
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Sasaki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000378:metabolism*; D012449:Safety; D015996:Survival Rate; D016896:Treatment Outcome; D014503:Urate Oxidase / Q000493:pharmacokinetics / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D006074:Gout Suppressants; D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase